These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 4891871)

  • 21. Treatment of myasthenia gravis by preventing acetylcholine receptor modulation.
    Losen M; Martínez-Martínez P; Phernambucq M; Schuurman J; Parren PW; De Baets MH
    Ann N Y Acad Sci; 2008; 1132():174-9. PubMed ID: 18567867
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Laryngeal manifestations of myasthenia. Apropos of a case affecting the dilator muscles of the glottis].
    Debain JJ; Lebrigand H; Freyss G
    Ann Otolaryngol Chir Cervicofac; 1968 Jun; 85(4):273-8. PubMed ID: 5706067
    [No Abstract]   [Full Text] [Related]  

  • 23. Acquired canine myasthenia gravis: immunocytochemical localization of immune complexes at neuromuscular junctions.
    Pflugfelder CM; Cardinet GH; Lutz H; Holliday TA; Hansen RJ
    Muscle Nerve; 1981; 4(4):289-95. PubMed ID: 7019698
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antigenic modulation of junctional acetylcholine receptor is not sufficient to account for the development of myasthenia gravis in receptor immunized mice.
    Berman PW; Heinemann SF
    J Immunol; 1984 Feb; 132(2):711-7. PubMed ID: 6690616
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Severity of myasthenia gravis is related to the degree of neuromuscular blocking effect by isoflurane].
    Kadosaki M; Enzan K; Horiguchi T; Komatsu H; Suzuki M
    Masui; 1993 Jun; 42(6):906-9. PubMed ID: 8320811
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Immunologic aspects of disorders of neuromuscular transmission. 2. Experimental autoimmune myasthenia gravis and the Lambert-Eaton myasthenic syndrome].
    Andreis I; Lovnićki TJ; Beara N; Taradi M
    Lijec Vjesn; 1994; 116(5-6):158-61. PubMed ID: 7968205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody.
    Punga AR; Flink R; Askmark H; Stålberg EV
    Muscle Nerve; 2006 Jul; 34(1):111-5. PubMed ID: 16453324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pathogenesis of myasthenia gravis].
    Téllez Zenteno JF; Morales Buenrostro LE; Torre Delgadillo A
    Rev Invest Clin; 2000; 52(1):80-5. PubMed ID: 10818814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The neuromuscular junction. Part II: myasthenia gravis.
    Brumback RA
    Am Fam Physician; 1981 Feb; 23(2):126-33. PubMed ID: 7457320
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis of myasthenia gravis.
    Br Med J; 1971 Apr; 2(5752):1-2. PubMed ID: 5550865
    [No Abstract]   [Full Text] [Related]  

  • 31. Effects of glucocorticoids on acetylcholine release at the neuromuscular junction [proceedings].
    Van Wilgenburg H
    Br J Pharmacol; 1980 Jan; 68(1):144P. PubMed ID: 7357158
    [No Abstract]   [Full Text] [Related]  

  • 32. [Myasthenia].
    Pinelli P; Tonali P
    Riv Neurobiol; 1974; 20(14):34-9. PubMed ID: 4377979
    [No Abstract]   [Full Text] [Related]  

  • 33. Myasthenia gravis: acetylcholine receptor antibodies and beyond.
    Burde RM
    J Clin Neuroophthalmol; 1981 Mar; 1(1):63-6. PubMed ID: 6213647
    [No Abstract]   [Full Text] [Related]  

  • 34. Acetylcholinesterase inhibitors in MG: to be or not to be?
    Punga AR; Stålberg E
    Muscle Nerve; 2009 Jun; 39(6):724-8. PubMed ID: 19260048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Congenital myasthenia: end-plate acetylcholine receptors and electrophysiology in five cases.
    Vincent A; Cull-Candy SG; Newsom-Davis J; Trautmann A; Molenaar PC; Polak RL
    Muscle Nerve; 1981; 4(4):306-18. PubMed ID: 7254233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacology of myasthenia gravis.
    Dipalma JR
    Am Fam Physician; 1980 Oct; 22(4):158-9. PubMed ID: 7424763
    [No Abstract]   [Full Text] [Related]  

  • 37. Myasthenia gravis.
    Rosenberg RN; Campbell J
    Calif Med; 1973 Jan; 118(1):18-23. PubMed ID: 4685942
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The neuromuscular junction with special reference to myasthenia gravis.
    Hubbard JI
    Proc Aust Assoc Neurol; 1965; 3():55-60. PubMed ID: 5881782
    [No Abstract]   [Full Text] [Related]  

  • 39. Treatment of ongoing experimental myasthenia gravis with short term high dose cyclophosphamide.
    Pestronk A; Drachman DB; Adams RN
    Muscle Nerve; 1982 Jan; 5(1):79-84. PubMed ID: 6977088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Single-fiber electromyography during menstrual exacerbation and ovulatory suppression in MuSK antibody-positive myasthenia gravis.
    Stickler DE; Stickler LL
    Muscle Nerve; 2007 Jun; 35(6):808-11. PubMed ID: 17221882
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.